Waldenstrom macroglobulinemia is sometimes known as Waldenstrom’s or WM. It’s a rare type of non-Hodgkin’s lymphoma. Lymphomas are cancers that start in cells called lymphocytes, a type of white blood ...
Waldenstrom macroglobulinemia (WM) is a rare form of non-Hodgkin’s lymphoma characterized by an overproduction of abnormal white blood cells. It’s a slow-growing type of blood cell cancer that affects ...
Waldenstrom macroglobulinemia (WM) is a rare type of cancer that affects the immune system. There are numerous treatments that may help, such as chemotherapy, immunotherapy, targeted drug therapy, and ...
FLORHAM PARK, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and ...
Brukinsa's approval is based on the ASPEN trial, showing a 28% very good partial response rate versus 19% with Imbruvica. Both Brukinsa and Imbruvica had a 78% overall response rate, but Brukinsa ...
CLR 131 shows promise in treating relapsed/refractory Waldenstrom’s macroglobulinemia, targeting B-cell malignancies with iodine-131 delivery. The trial will enroll 50 patients, administering up to ...
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
FLORHAM PARK, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results